Brief: Medipost receives Canada patent
28/06/2017 04:43
June 28 (Reuters) - Medipost Co Ltd 078160.KQ :
* Says it received Canada patent on June 28, for composition
comprising mesenchymal stem cells or culture solution of
mesenchymal stem cells for the prevention or treatment of neural
diseases
* Patent number is 2,743,620
Source text in Korean: https://goo.gl/nsXB1w
Further company coverage: 078160.KQ
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America